Category: Health Newsfeed
What can we learn from nurses about how to sustain them in stressful times? Elizabeth Tracey reports
A confirmatory trial for a new Alzheimer’s disease drug is many years away, Elizabeth Tracey reports
Podcast: Download (Duration: 1:06 — 1.5MB)
Subscribe: RSS
Medicare is poised to spend millions of dollars on aducanumab, a just approved drug for Alzheimer’s disease the FDA’s own advisory panel recommended against approving. Caleb Alexander, a member of the panel and an internal medicine expert at Johns Hopkins, …
Why is a new Alzheimer’s drug so controversial? Elizabeth Tracey reports
Podcast: Download (Duration: 1:03 — 1.5MB)
Subscribe: RSS
Is amyloid, a substance that accumulates in the brains of people with Alzheimer’s disease, the cause of the disease or simply a bystander? No one knows, and that’s why an FDA advisory panel voted against approving a new drug to …
Why is a new Alzheimer’s drug so controversial? Elizabeth Tracey reports Read more »
How should drug effectiveness in Alzheimer’s disease be measured? Elizabeth Tracey reports
Podcast: Download (Duration: 1:02 — 1.4MB)
Subscribe: RSS
The amyloid hypothesis. That’s the idea that accumulation of a material called amyloid in the brain leads to Alzheimer’s disease. Acceptance of this idea has led the FDA to approve aducanumab, which reduces amyloid, but isn’t known to improve any …
How did Anuhelm, a new drug for Alzheimer’s disease, get approved? Elizabeth Tracey reports
Podcast: Download (Duration: 1:03 — 1.5MB)
Subscribe: RSS
Aducanumab or Aduhelm is a newly approved medicine for treating Alzheimer’s disease, with many experts asserting that it should never have gotten FDA approval. Caleb Alexander, an internal medicine expert at Johns Hopkins and a member of the FDA review …
Should a new Alzheimer’s drug have been approved by the FDA? Elizabeth Tracey reports
Podcast: Download (Duration: 1:04 — 1.5MB)
Subscribe: RSS
Aduhelm is the proprietary name for aducanumab, a just approved medication for treatment of Alzheimer’s disease. Caleb Alexander, an internal medicine expert at Johns Hopkins, sat on the FDA review board for this medicine and explains why he voted no …
Should a new Alzheimer’s drug have been approved by the FDA? Elizabeth Tracey reports Read more »